 |
Prospector
Profile
07.1248
|
| |
| Middlebrook Pharmaceuticals, Inc. |
NAICS |
541710 |
| 20425 Seneca Meadows Parkway
Germantown, MD 20876 |
Description |
Biotechnology |
| (301) 944-6600 |
Employees |
76 |
| http://www.middlebrookpharma.com/ |
Revenue |
(mil) |
4.8100 |
| |
Income |
(mil) |
-41.9900 |
| |
Assets |
(mil) |
42.0100 |
| |
Liability |
(mil) |
30.1300 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Middlebrook Pharmaceuticals, Inc. reported a net loss of $9,477,927 on revenues of $2,680,558 for the second quarter ended June 30, 2007, a decrease over the $10,725,547 net loss on revenues of $336,357 reported during the second quarter of last year. For the first half of 2007, the Company recognized a net loss of $23,140,917 on revenues of $4,453,595, compared to a $18,322,897 net loss on revenues of $1,196,588 reported during the first half of 2006. The Company's balance sheet showed an accumulated deficit of $176,226,379 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company seeks to protect proprietary position by, among other methods, filing U.S. and foreign patent applications related to proprietary technology, inventions and improvements that are important to the development of its business. In addition, the Company intends to use license agreements to access external products and technologies, as well as to convey its intellectual property to others. The Company currently owns 25 issued U.S. patents, 23 U.S. patent applications and 2 foreign patents. The issued patents cover certain compositions and methods using pulsatile dosing. It also owns 67 foreign-filed patent applications, which correspond to U.S. patents and applications. It also owns 4 PCT patent applications. [SEC Filing 10-K 03-26-07]
|
| |
|
Description:
The Company, formerly known as Advancis Pharmaceuticals, Inc., engages in the development and commercialization of anti-infective drug products for the treatment of infectious diseases.
|
| |
|
Officers:
R. Gordon Douglas, M.D. (Chair); Edward M. Rudnic, Ph.D. (Pres., CEO & Dir.); Robert C. Low (VP, CFO & Treas.); Richard W. Dugan (Dir.); James H. Cavanaugh, Ph.D. (Dir.); Harold R. Werner (Dir.); Wayne T. Hockmeyer, Ph.D. (Dir.)
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock-Symbol MBRK; NasdaqGM;
46,651,559 common shares outstanding as of August 8, 2007.
|
| |
| |
| |
| return to main page |
|
|
